Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.20)
# 2,841
Out of 5,090 analysts
119
Total ratings
38.32%
Success rate
-1.69%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYBN Cybin | Maintains: Buy | $70 → $45 | $5.99 | +651.25% | 9 | Nov 20, 2025 | |
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $16 → $25 | $12.35 | +102.43% | 2 | Nov 7, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $25 → $24 | $8.71 | +175.55% | 7 | Nov 6, 2025 | |
| STOK Stoke Therapeutics | Maintains: Buy | $24 → $28 | $30.87 | -9.30% | 4 | Nov 5, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $160 → $164 | $155.51 | +5.46% | 17 | Oct 29, 2025 | |
| ATAI Atai Beckley | Maintains: Buy | $11 → $14 | $4.32 | +224.07% | 4 | Oct 22, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $17 | $4.55 | +273.63% | 4 | Sep 30, 2025 | |
| CLNN Clene | Maintains: Buy | $83 → $48 | $5.77 | +731.89% | 6 | Aug 18, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $15 | $5.82 | +157.73% | 4 | Aug 1, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $8.69 | +210.70% | 6 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $265 → $220 | $181.30 | +21.35% | 21 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $4.28 | +180.37% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $2.07 | +3,764.73% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $14.89 | +88.05% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $27.44 | +20.26% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $9.55 | +1,470.68% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $28.46 | - | 2 | Jan 31, 2017 |
Cybin
Nov 20, 2025
Maintains: Buy
Price Target: $70 → $45
Current: $5.99
Upside: +651.25%
Mind Medicine (MindMed)
Nov 7, 2025
Maintains: Buy
Price Target: $16 → $25
Current: $12.35
Upside: +102.43%
Zevra Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $25 → $24
Current: $8.71
Upside: +175.55%
Stoke Therapeutics
Nov 5, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $30.87
Upside: -9.30%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Buy
Price Target: $160 → $164
Current: $155.51
Upside: +5.46%
Atai Beckley
Oct 22, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $4.32
Upside: +224.07%
Annovis Bio
Sep 30, 2025
Maintains: Buy
Price Target: $17
Current: $4.55
Upside: +273.63%
Clene
Aug 18, 2025
Maintains: Buy
Price Target: $83 → $48
Current: $5.77
Upside: +731.89%
COMPASS Pathways
Aug 1, 2025
Maintains: Buy
Price Target: $15
Current: $5.82
Upside: +157.73%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $8.69
Upside: +210.70%
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $181.30
Upside: +21.35%
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $4.28
Upside: +180.37%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $2.07
Upside: +3,764.73%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $14.89
Upside: +88.05%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $27.44
Upside: +20.26%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $9.55
Upside: +1,470.68%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $28.46
Upside: -